<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698915</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4711-201</org_study_id>
    <nct_id>NCT04698915</nct_id>
  </id_info>
  <brief_title>Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer</brief_title>
  <official_title>GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind,&#xD;
      placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following&#xD;
      chemotherapy in patients with unresectable or borderline resectable nonmetastatic&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival after SBRT completion</measure>
    <time_frame>From randomization up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival after SBRT Completion per RESIST 1.1</measure>
    <time_frame>From randomization up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>SBRT</condition>
  <condition>Borderline Resectable Pancreatic Cancer</condition>
  <condition>Unresectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A Active GC4711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug GC4711</intervention_name>
    <description>15 Minute IV Infusion</description>
    <arm_group_label>Arm A Active GC4711</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>15 Minute IV Infusion</description>
    <arm_group_label>Arm B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable&#xD;
             if histology cannot be obtained.&#xD;
&#xD;
          2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for&#xD;
             (m)FOLFIRINOX and SBRT&#xD;
&#xD;
          3. Remains non-metastatic (i.e., M0 disease) after 3 months of chemotherapy&#xD;
&#xD;
          4. Female or male subjects â‰¥ 18 years of age&#xD;
&#xD;
          5. ECOG performance status of 0-2&#xD;
&#xD;
          6. Adequate end-organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with documented metastatic disease&#xD;
&#xD;
          2. First-line chemotherapy other than (m)FOLFIRINOX and/or chemotherapy given for a total&#xD;
             period of longer than 4 months prior to start of SBRT&#xD;
&#xD;
          3. Prior abdominal RT with substantial overlap in radiation fields&#xD;
&#xD;
          4. Subjects not recovered/controlled from treatment-related toxicities&#xD;
&#xD;
          5. Uncontrolled malignancy other than PC&#xD;
&#xD;
          6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing&#xD;
&#xD;
          7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Terry</last_name>
    <phone>610-725-1500</phone>
    <email>kterry@galeratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon Holmlund, MD</last_name>
    <phone>610-725-1500</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Walker, MD</last_name>
      <phone>480-878-2022</phone>
    </contact>
    <investigator>
      <last_name>Gary Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uma Goyal, MD</last_name>
      <phone>520-694-2873</phone>
    </contact>
    <investigator>
      <last_name>Uma Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Kamrava, MD</last_name>
      <phone>310-423-3277</phone>
    </contact>
    <investigator>
      <last_name>Mitchell Kamrava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Bodeker</last_name>
      <phone>319-384-6332</phone>
    </contact>
    <investigator>
      <last_name>Joseph Caster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Akhavan</last_name>
      <phone>913-588-6046</phone>
    </contact>
    <investigator>
      <last_name>David Akhavan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Parikh, MD</last_name>
      <phone>313-916-2600</phone>
    </contact>
    <investigator>
      <last_name>Parag Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maged Ghaly, MD</last_name>
      <phone>516-390-9242</phone>
    </contact>
    <investigator>
      <last_name>Maged Ghaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manisha Palta, MD</last_name>
      <phone>919-684-8111</phone>
    </contact>
    <investigator>
      <last_name>Manisha Palta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Anderson</last_name>
      <phone>216-844-8447</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Dorth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Arterburn</last_name>
      <phone>405-271-8001</phone>
    </contact>
    <investigator>
      <last_name>Sagila George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology and Gamma Knife Center of Oregon</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Seung, MD</last_name>
      <phone>503-215-6800</phone>
    </contact>
    <investigator>
      <last_name>Steven Seung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Robles</last_name>
      <phone>215-645-4673</phone>
    </contact>
    <investigator>
      <last_name>Todd Aguilera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Nichols</last_name>
      <phone>540-808-1704</phone>
    </contact>
    <investigator>
      <last_name>Mark Kochenderfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Gunderson, MD</last_name>
      <phone>509-228-1000</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Gunderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

